<DOC DOCNO="nw/wsj/19/wsj_1956@1956@wsj@nw@en@on">
<ENAMEX TYPE="ORG">National Patent Development Corp.</ENAMEX> said it plans to purchase <ENAMEX TYPE="CARDINAL">as many as 200,000</ENAMEX> common shares of its <ENAMEX TYPE="PERCENT">81 %</ENAMEX> - controlled <ENAMEX TYPE="ORG">Interferon Sciences Inc.</ENAMEX> unit in periodic , open - market purchases .
The <ENAMEX TYPE="CARDINAL">200,000</ENAMEX> shares are <ENAMEX TYPE="PERCENT">about 23 %</ENAMEX> of <ENAMEX TYPE="ORG">Interferon</ENAMEX> 's common shares outstanding , excluding <ENAMEX TYPE="ORG">National Patent 's</ENAMEX> stake .
Noting the recent <ENAMEX TYPE="ORG">Food and Drug Administration</ENAMEX> approval of <ENAMEX TYPE="ORG">Interferon</ENAMEX> 's genital warts treatment , <ENAMEX TYPE="ORG">National Patent</ENAMEX> said it believes <ENAMEX TYPE="ORG">Interferon</ENAMEX> 's stock is undervalued .
</DOC>
